BioPharma Dive July 5, 2022
Highly anticipated study readouts in cancer, Alzheimer’s disease and schizophrenia could determine whether the biotech industry’s slump continues.
Can the biotechnology industry regain its footing after months of sliding stock values and setbacks?
Recently, there have been some positive signs. Dealmaking has picked up. Drug pricing reform — a persistent concern for the industry and its investors — hasn’t advanced. Notable medical advances have come this year...
Today's Sponsors
Today's Sponsor